Rising GLP-1 Pill Adoption Boosts Eli Lilly Outlook; West Pharma Sees 2026 Profit Beat
McDonald’s warns of shifting consumer patterns as GLP-1 weight-loss pills hit the market, prompting menu adjustments and signaling stronger demand for Eli Lilly’s semaglutide offerings. West Pharma projects 2026 profit above analyst estimates, attributing growth to robust demand for injectable drug components that could support Eli Lilly’s manufacturing supply chain.
1. McDonald’s Prepares for GLP-1 Pill Adoption
McDonald’s executives report that as GLP-1 weight-loss drugs like semaglutide become widely available, consumer ordering patterns are changing. The company is exploring menu revisions and promotional strategies to counter potential traffic declines while acknowledging the opportunity from increased semaglutide prescriptions.
2. West Pharma Raises 2026 Profit Outlook
West Pharma has forecast 2026 profit above the consensus estimate, citing strong order volumes for prefilled syringes, vials and other injectable drug components. The company believes sustained demand will bolster capacity investments and streamline the supply chain for major manufacturers, including Eli Lilly.